Yandex injects 600G wavelengths into DCI network with ADVA TeraFlex™
5.11.2020 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Yandex has transformed its data center interconnect (DCI) infrastructure into a 600Gbit/s transport network using the ADVA FSP 3000 TeraFlex™. The solution massively increases the capacity of Yandex’s infrastructure throughout Moscow, enabling Russia’s largest search engine provider to meet rapidly rising data demands and expand its cloud services. Delivering high levels of throughput, density and scale, the technology easily plugged into Yandex’s existing line system. ADVA’s open TeraFlex™ terminal supports 600Gbit/s over a single wavelength and delivers a total duplex capacity of 3.6Tbit/s in one rack unit. With its low power consumption and ultra-flexible modulation capabilities, TeraFlex™ ensures maximum spectral efficiency, making Yandex’s DCI network future-proof and highly efficient.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201105005031/en/
ADVA's TeraFlex™ technology is helping Yandex to easily scale its DCI network (Photo: Business Wire)
“We’re proud of what our FSP 3000 TeraFlex™ technology is helping Yandex achieve. Without the effort or expense of a complete system upgrade, it’s enabled one of Russia’s biggest technology companies to transform its infrastructure. By unlocking the full value of its fiber assets, Yandex is opening the door to further growth and innovation,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our TeraFlex™ has a large degree of configuration flexibility, using different modulation formats and software-defined fractional QAM to optimize data rate transmission performance. Together with its plug-and-play simplicity, TeraFlex™ made it easy for Yandex to transform its existing DCI infrastructure.”
Yandex’s Moscow data centers are now connected in a point-to-point network with ADVA’s high-density TeraFlex™ terminal. Serving 36 bidirectional 100GbE client ports, the 1RU solution injects new levels of channel capacity and spectral efficiency into Yandex’s network. Built specifically to maximize fiber utilization, TeraFlex™ features software-defined fractional QAM modulation capabilities. This enables it to leverage different modulation formats and optimize all optical paths over any distance.
“We’re helping Yandex to massively expand the capacity of its network and accommodate ever-increasing traffic demands. Our TeraFlex™ terminal is ensuring that one of Russia’s leading technology companies can meet its customers’ expectations and continue growing its business well into the future,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “Tens of millions of people rely on Yandex’s products and services on a daily basis. That’s why it’s a company keen to deliver even more by leveraging the most advanced technology on the market. Our solution enables it to continue innovating and improving quality. And, with the space- and power-efficiency of TeraFlex™, Yandex’s new network also ensures that future growth is fully sustainable.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005031/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
